
Annick Tibi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11362205/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. JAMA Internal Medicine, 2021, 181, 32.	5.1	654
2	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	7.4	498
3	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 295-304.	10.7	232
4	Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1. Neuro-Oncology, 2006, 8, 60-66.	1.2	189
5	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro-Oncology, 2010, 12, 401-408.	1.2	180
6	Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial. PLoS Medicine, 2010, 7, e1000362.	8.4	108
7	Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma—A phase II multicentric, randomised study. European Journal of Cancer, 2017, 73, 30-37.	2.8	68
8	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatology, The, 2022, 4, e24-e32.	3.9	34
9	Effect of Oseltamivir, Zanamivir or Oseltamivir– Zanamivir Combination Treatments on Transmission of Influenza in Households. Antiviral Therapy, 2012, 17, 1085-1090.	1.0	30
10	lmmunotherapy with CpGâ€ <scp>ODN</scp> in neoplastic meningitis: A phase I trial. Cancer Science, 2015, 106, 1212-1218.	3.9	24
11	Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group. EClinicalMedicine, 2022, 46, 101362.	7.1	20
12	Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial. BMJ Open, 2017, 7, e014546.	1.9	8